Related Experiment Video
Updated: Mar 5, 2026
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
The miR-30 family: Versatile players in breast cancer
Su-Jin Yang1,2, Su-Yu Yang3, Dan-Dan Wang1,2
11 The Fourth Clinical School of Nanjing Medical University, Nanjing, China.
Abstract:
The microRNA family, miR-30, plays diverse roles in regulating key aspects of neoplastic transformation, metastasis, and clinical outcomes in different types of tumors. Accumulating evidence proves that miR-30 family is pivotal in the breast cancer development by controlling critical signaling pathways and relevant oncogenes. Here, we review the roles of miR-30 family members in the tumorigenesis, metastasis, and drug resistance of breast cancer, and their application to predict the prognosis of breast cancer patients. We think miR-30 family members would be promising biomarkers for breast cancer and may bring a novel insight in molecular targeted therapy of breast cancer.
Insights
The miR-30 family is crucial in breast cancer development, influencing tumor growth, spread, and treatment response. These microRNAs show promise as biomarkers and in targeted therapy for breast cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The miR-30 microRNA family regulates key processes in cancer, including neoplastic transformation and metastasis.
- Evidence highlights the miR-30 family's critical role in breast cancer development by controlling oncogenes and signaling pathways.
Purpose of the Study:
- To review the functions of miR-30 family members in breast cancer.
- To explore their roles in tumorigenesis, metastasis, and drug resistance.
- To assess their potential as prognostic biomarkers and in targeted therapy.
Main Methods:
- Literature review of studies on miR-30 family in breast cancer.
- Analysis of miR-30's involvement in key cancer signaling pathways.
- Evaluation of clinical data regarding miR-30 expression and patient outcomes.
Main Results:
- miR-30 family members are implicated in regulating breast cancer cell proliferation and invasion.
- Dysregulation of miR-30 impacts response to various breast cancer treatments.
- Specific miR-30 members correlate with patient prognosis and survival rates.
Conclusions:
- The miR-30 family is pivotal in breast cancer progression and therapeutic response.
- miR-30 members represent potential biomarkers for breast cancer prognosis.
- Targeting the miR-30 family may offer novel therapeutic strategies for breast cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...